Wednesday, October 07, 2026 CXC2 is a Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal CancerIncorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006This randomized phase III trial studied radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy (RT) uses high energy protons to kill tumor cells and shrink tumors. While the addition of T did not improve overall survibal compared to CRT alone, several important findings and applications for the continued management and improvement in outcomes in patients with LACC were noted. CC control may be better than previously assessed in NCI clinical trials and IMRT was validated as a safe, feasible and effective radiation modality for the definitive setting for women with LACC. Rapid centralized pre-treatment review for complex RT planning was implemented and is potentially exportable as a method to support utilization of IG-IMRT and other complex planning approaches in LACC through a large cooperative group network. Leath CA, III, Deng W, Mell LK, Richardson DL, Walker JL, Holman LL, Lea JS, Amarnath SR, Santos-Reyes LJ, Arend RC, Mayadev J, Jegadeesh N, DiSilvestro P, Chon HS, Ghamande SA, Gao L, Albuquerque K, Chino JP, Donnelly E, Feddock JM, Lowenstein J, Quick AM, Kunos CM, MacKay H, Aghajanian C, Monk BJ. Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecologic Oncology 195: 122-133. 2025. https://doi.org/10.1016/j.ygyno.2025.03.007 This study was funded through the US National Cancer Institute and lead by NRG Oncology group (NRG-GY006) (NCT02466971)
